74 related articles for article (PubMed ID: 20026675)
1. A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors.
Soriano A; Vendrell M; Gonzalez S; Mallol J; Albericio F; Royo M; Lluís C; Canela EI; Franco R; Cortés A; Casadó V
J Pharmacol Exp Ther; 2010 Mar; 332(3):876-85. PubMed ID: 20026675
[TBL] [Abstract][Full Text] [Related]
2. Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 dopamine receptors.
Vendrell M; Soriano A; Casadó V; Díaz JL; Lavilla R; Canela EI; Lluís C; Franco R; Albericio F; Royo M
ChemMedChem; 2009 Sep; 4(9):1514-22. PubMed ID: 19557804
[TBL] [Abstract][Full Text] [Related]
3. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
[TBL] [Abstract][Full Text] [Related]
5. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
[TBL] [Abstract][Full Text] [Related]
6. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions.
Jutkiewicz EM; Bergman J
J Pharmacol Exp Ther; 2004 Dec; 311(3):1008-15. PubMed ID: 15292458
[TBL] [Abstract][Full Text] [Related]
7. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
Ryman-Rasmussen JP; Nichols DE; Mailman RB
Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
Ralph RJ; Caine SB
J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
[TBL] [Abstract][Full Text] [Related]
10. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
11. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway.
Santanavanich C; Ebadi M; Govitrapong P
J Pineal Res; 2005 Apr; 38(3):170-5. PubMed ID: 15725338
[TBL] [Abstract][Full Text] [Related]
13. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
15. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A1 receptor-mediated inhibition of dopamine release from rat striatal slices is modulated by D1 dopamine receptors.
O'Neill C; Nolan BJ; Macari A; O'Boyle KM; O'Connor JJ
Eur J Neurosci; 2007 Dec; 26(12):3421-8. PubMed ID: 18052983
[TBL] [Abstract][Full Text] [Related]
17. Negative feedback regulation of nigrostriatal dopamine release: mediation by striatal D1 receptors.
Saklayen SS; Mabrouk OS; Pehek EA
J Pharmacol Exp Ther; 2004 Oct; 311(1):342-8. PubMed ID: 15175419
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 6-substituted 1-phenylbenzazepines and their dopamine D(1) receptor activities.
Zhang J; Chen X; Yu L; Zhen X; Zhang A
Bioorg Med Chem; 2008 Nov; 16(21):9425-31. PubMed ID: 18835172
[TBL] [Abstract][Full Text] [Related]
19. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
[TBL] [Abstract][Full Text] [Related]
20. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
Wirtshafter D; Osborn CV
Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
